Subtype
Throat Carcinoma
CI-CAN-00006917Explore in graph →
369 active trials1 approved drugs2 evidence items
- NCIt
- C35506
Loading cancer entity…
Subtype
CI-CAN-00006917Explore in graph →
Clinical trials
1,035 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (87)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06612697 | Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone | active not recruiting | — | 262 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 |
| Sep 24, 2024 |
| clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04220307 | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 34 | AkesoINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05517135 | tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella) | recruiting | — | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06314711 | Ex Vivo 3D-ultrasound for Oropharyngeal Cancer | completed | N/A | 15 | Rigshospitalet, DenmarkOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06463756 | AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma | unknown | — | 400 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04417985 | Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma | completed | N/A | 112 | Chang Gung Memorial HospitalOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT05892354 | Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy | recruiting | N/A | 190 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06170021 | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy | unknown | — | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06533267 | Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. | recruiting | N/A | 442 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06529562 | Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma. | recruiting | N/A | 384 | Ming-Yuan ChenOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06523933 | Distribution of Bacteria in OME After Radiotherapy For NPC. | unknown | — | 234 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT05193617 | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT05330169 | Hearing Impairment of Nasopharyngeal Carcinoma | completed | — | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | recruiting | Phase 3 | 164 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 162 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490341 | GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06486220 | PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial. | unknown | Phase 3 | 96 | Yun-fei XiaOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06480903 | Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy(ClearED) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT06472024 | Assessing Manual Acupuncture's Impact on Mucositis From Nasopharynx Cancer Radiotherapy: A Visual Analogue Scale (VAS) and Quality of Life Study | unknown | N/A | 30 | Indonesia UniversityOTHER | 0 | Jun 26, 2024 | clinicaltrials |
| NCT06445088 | Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma | recruiting | — | 908 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06455410 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 216 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05513573 | Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC | active not recruiting | Phase 2 | 75 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06442709 | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients | unknown | N/A | 100 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04995185 | 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study | completed | N/A | 9 | National Cancer Centre, SingaporeOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06019130 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma(NPC-Nivo) | recruiting | Phase 2 | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbHOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04396886 | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | completed | Phase 2 | 38 | The University of Hong KongOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT02072148 | The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) | completed | N/A | 112 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03025958 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06370026 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04557020 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | unknown | Phase 3 | 200 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06282497 | Xerostomia-optimised IMRT Versus Standard IMRT in NPC | recruiting | N/A | 524 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05858385 | Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients | unknown | — | 700 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Sep 25, 2024source: clinicaltrials